Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Genfit

Status and phase: Terminated; Phase 2

Conditions: Non-Alcoholic Fatty Liver

Treatments: Drug: elafibranor 120mg; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT03953456

2019-000645-12 (EudraCT Number)

GFT505-219-8

Details and patient eligibility

About

This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an adult NAFL population after 6 weeks of treatment with a 4-week wash-out period. This study will achieve mechanistic information about the mode of action of Elafibranor on the (lipid) metabolism in the human fatty liver

Enrollment: 17 patients

Sex: All

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or post-menopausal females aged from 40-75 years inclusive at first Screening Visit. (Post-menopausal defined as: subject should be surgically sterilized at least 6 months or no spontaneous menses for at least 1 year prior to screening)
• Must provide signed written informed consent and agrees to comply with the study protocol.
• Liver fat percentage ≥ 5 percent (as measured with Magnetic Resonance Spectroscopy)
• 25.0 ≤ BMI ≤ 38.0 kg/m^2
• Stable dietary habits and physical activity pattern (over 3 months prior to Screening Visit)
• Subject agrees not to change dietary habits and physical activity pattern, to follow diet and lifestyle recommendations and not to consume or use illicit drugs during the study up to end of treatment.

Exclusion criteria

Medical history:

• Documented weight loss of more than 5 percent during the 6-month period prior to Screening Visit
• Contra-indications for magnetic resonance imaging / spectroscopy
• Known history of Type 1 and 2 diabetes
• Known chronic heart failure (Grade I to IV of New York Heart Association classification)
• History of clinically significant acute cardiac event within 6 months prior to Screening Visit such as: stroke, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures)
• Uncontrolled hypertension despite optimal antihypertensive therapy
• Other well documented causes of chronic liver disease according to standard diagnostic procedures.
• Symptoms of clinical depression
• Other concurrent medical (e.g., immunological, neoplastic, endocrine, hematological, gastrointestinal or neurological) or psychiatric condition, which, in the opinion of the Investigator, would place the subject at increased risk, preclude obtaining voluntary consent/assent or compliance with required study procedures, or would confound the objectives of study
• Known hypersensitivity to the investigation product or any of its formulation excipients

Concomitant medications and lifestyle:

• Fibrates are not permitted from 8 weeks before Screening up to end of treatment. Subjects taking statins or ezetimibe prior to Screening Visit 1 may participate if the dose has been stable for 3 months prior to Screening Visit 1 and no dose adjustments are anticipated
• Currently taking drugs that can induce steatosis/steatohepatitis including, but not restricted to: corticosteroids (parenteral & oral chronic administration only), amiodarone (Cordarone), tamoxifen (Nolvadex), and methotrexate (Rheumatrex, Trexall), which are not permitted 30 days prior to Screening and up to end of treatment
• Subjects receiving thiazolidinediones (glitazones [pioglitazone, rosiglitazone])
• Currently taking any medication that could interfere with study medication absorption, distribution, metabolism, or excretion or could lead to induction or inhibition of microsomal enzymes, e.g., indomethacin, which are not permitted from Randomization until end of treatment
• Any medication use known to interfere with glucose homeostasis/metabolism
• Smoking
• Current or recent history (<5years) of significant alcohol consumption. For men, significant consumption is typically defined as higher than 30 g pure alcohol per day. For women, it is typically defined as higher than 20 g pure alcohol per day
• Subjects who have donated blood or blood products within the previous month prior to screening or who plan to donate blood or blood products at any time during the trial and in the month following the end of the study
• Is participating in any other study and have received any other investigational drug or device within 30 days prior to Screening or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with study compliance or outcome assessments
• Subjects who cannot be contacted in case of emergency

In addition to the above criteria, subject should not present any of the following biological exclusion criteria:

• Positive anti-human immunodeficiency virus (HIV) antibody
• Positive hepatitis B surface antigen
• Positive hepatitis C Virus (HCV) antibody
• Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >5 x upper limit of normal (ULN)
• Conjugated bilirubin > 1.50mg/dL due to altered hepatic function Note: Gilbert Disease subjects are allowed into the study
• International normalized ratio >1.40 due to altered hepatic function
• Platelet count <100,000/mm^3 due to portal hypertension
• Serum creatinine levels >1.53 mg/dL in males and >1.24 mg/dL in females
• Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as subjects with markers of kidney damage or estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m^2)
• Unexplained serum creatine phosphokinase (CPK) >2 x ULN. In case of explained elevated CPK >2 x ULN, the measurement can be repeated prior to Randomization. In this case, retest should be performed within 1 to 2 weeks after initial test. A CPK retest >2 x ULN leads to exclusion
• Hemoglobin A1c (HbA1C) > 6.4% and/or fasting plasma glucose (FGP) > 126 mg/dl

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

17 participants in 2 patient groups, including a placebo group

elafibranor 120mg followed by placebo

Experimental group

Description:

Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks

Treatment:

Drug: Placebo

Drug: elafibranor 120mg

placebo followed by elafibranor 120mg

Placebo Comparator group

Description:

Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks

Treatment:

Drug: Placebo

Drug: elafibranor 120mg